

**AMENDMENTS TO THE CLAIMS**

The following listing of claims will replace all prior versions and listings of claims in the Application.

**Listing of Claims**

1-54. (Canceled)

55. (Currently Amended) A kit for detecting HIV-2 nucleic acids, comprising **a packaged combination of the following components in one or more containers:**

(a) a first amplification oligonucleotide **that consists of SEQ ID NO:10 and optionally comprises a 5' promoter sequence non-complementary to the HIV-2 nucleic acid** [~~comprising a sequence of 9-34 contiguous bases contained within the sequence of SEQ ID NO:9, said first amplification oligonucleotide having a length of up to 100 nucleotides~~]; and

(b) a second amplification oligonucleotide comprising a sequence of 19-40 contiguous bases from the sequence of SEQ ID NO:1, said second amplification oligonucleotide having a length of up to 100 nucleotides.

56. (Original) The kit of Claim 55, further comprising:

(c) an oligonucleotide detection probe that comprises the sequence of SEQ ID NO:21 or the complement thereof, and a detectable label.

57. (Previously Presented) The kit of Claim 55, wherein the length of the second amplification oligonucleotide is 19-40 nucleotides.

58. (Currently Amended) The kit of Claim 57, wherein the length of the first amplification oligonucleotide is **up to 60** [[18-60]] nucleotides.

59-61. (Canceled)

62. **(Currently Amended)** The kit of Claim 57, wherein the length of the first amplification oligonucleotide is ~~[[18-60]]~~ **up to 60** nucleotides, ~~[[and]]~~ wherein the first amplification oligonucleotide ~~further comprises a~~ **includes said optional 5'** promoter sequence.

63. **(Previously Presented)** The kit of Claim 57, wherein the length of the second amplification oligonucleotide is 19-21 nucleotides.

64. **(Canceled)**

65. **(Previously Presented)** The kit of Claim 58, wherein the length of the second amplification oligonucleotide is 19-21 nucleotides.

66. **(Currently Amended)** The kit of Claim 62, wherein the first amplification oligonucleotide is ~~[[a]]~~ **the** promoter-primer ~~selected from the group consisting of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19.~~

67. **(Previously Presented)** The kit of Claim 65, wherein the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.

68. **(Currently Amended)** The kit of Claim 65, wherein the first amplification oligonucleotide ~~further comprises a~~ **includes said optional 5'** promoter sequence.

69. **(Currently Amended)** The kit of Claim 68, wherein the first amplification oligonucleotide is ~~[[a]]~~ **the** promoter-primer ~~selected from the group consisting of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19.~~

70. **(Previously Presented)** The kit of Claim 68, wherein the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.

71. **(Previously Presented)** The kit of Claim 69, wherein the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.

72. **(Currently Amended)** The kit of Claim 55, wherein the length of the first amplification oligonucleotide is ~~[[18-25]]~~ **25** nucleotides, and wherein the length of the second amplification oligonucleotide is 19-21 nucleotides.

73. **(Canceled)**
74. **(Previously Presented)** The kit of Claim 72, wherein the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.
75. **(Currently Amended)** The kit of Claim ~~[[73]]~~ 72, wherein the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.
76. **(Previously Presented)** The kit of Claim 56, wherein said oligonucleotide detection probe has a length of up to 18 nucleotides.
77. **(Previously Presented)** The kit of Claim 76, wherein the sequence of said oligonucleotide detection probe is selected from the group consisting of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.
78. **(Currently Amended)** The kit of Claim 77, wherein the sequence of the first amplification oligonucleotide is ~~selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19,~~ wherein the sequence of the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, and wherein the sequence of the oligonucleotide detection probe is selected from the group consisting of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.
79. **(Previously Presented)** The kit of Claim 56, wherein said oligonucleotide detection probe has a length of up to 35 nucleotides.
80. **(Previously Presented)** The kit of Claim 79, wherein the length of said oligonucleotide detection probe is up to 22 nucleotides.
81. **(Previously Presented)** The kit of Claim 80, wherein said oligonucleotide detection probe comprises at least 16 contiguous nucleotides contained within the sequence of SEQ ID NO:20 or the complement thereof.

82. **(Previously Presented)** The kit of Claim 81, wherein said oligonucleotide detection probe has the sequence of SEQ ID NO:20 or the complement thereof.

83. **(Previously Presented)** The kit of Claim 81, wherein said oligonucleotide detection probe has a length of up to 18 nucleotides.

84. **(Previously Presented)** The kit of Claim 83, wherein the length of said oligonucleotide detection probe is 18 nucleotides.

85. **(Previously Presented)** The kit of Claim 83, wherein said oligonucleotide detection probe has a sequence selected from the group consisting of SEQ ID NO:22 or the complement thereof, SEQ ID NO:23 or the complement thereof, SEQ ID NO:24 or the complement thereof, SEQ ID NO:25 or the complement thereof, SEQ ID NO:26 or the complement thereof, and SEQ ID NO:27 or the complement thereof.

86. **(Previously Presented)** The kit of Claim 79, wherein said oligonucleotide detection probe comprises DNA.

87. **(Previously Presented)** The kit of Claim 79, wherein said oligonucleotide detection probe comprises at least one nucleotide analog.

88. **(Previously Presented)** The kit of Claim 87, wherein said at least one nucleotide analog comprises a methoxy group at the 2' position of a ribose moiety.

89. **(Previously Presented)** The kit of Claim 85, wherein the detectable label is a chemiluminescent label or a radiolabel.

90. **(Previously Presented)** The kit of Claim 89, wherein the detectable label is an acridinium ester.

App. Serial No. 10/001,407  
Amendment dated Aug. 19, 2004  
Reply to Office Action of Mar. 23, 2004

**REPLACEMENT OF THE SEQUENCE LISTING**

Please remove the original paper version of the Sequence Listing from the Application.  
Please insert the enclosed Substitute Sequence Listing pages 1-6 after page 51 of the  
Specification.

A computer-readable form of the Substitute Sequence Listing is also enclosed.